CareOsis Linzosis 600
CareOsis Linzosis 600 (Linezolid Tablets IP 600 mg): a reliable oral option for serious and resistant Gram positive infections, with oral bioavailability comparable to IV therapy.
Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex, and is active against multi-drug resistant Gram positive pathogens including MRSA and VRE.
Everything you need
to know before you decide
Key Features
- Active against MDR Gram positive pathogens
- Effective in serious & resistant infections
- 100% oral bioavailability for better compliance
- Well tolerated with predictable safety
- Suitable for hospital & community use
Health Benefits
- Potent activity against resistant Gram positive pathogens
- Excellent penetration into lung & soft tissues
- Reduces hospital stay & improves patient outcomes
Directions for Use
Dosage
One tablet (600 mg) every 12 hours, or as directed by the physician.
Complete the course
Complete the full antibiotic course as prescribed, even if symptoms improve earlier.
Every ingredient
has a purpose
Linezolid
Inhibits bacterial protein synthesis, effective against nosocomial pneumonia, complicated skin & soft tissue infections, intra-abdominal infections and Vancomycin Resistant Enterococcal (VRE) infections.
| Common Name | Concentration |
|---|---|
| Linezolid | 600 mg |